Cellceutix nabs antibiotic in bankruptcy fire sale; Lawmaker urges BioMarin to act on compassionate-use petition;

@FierceBiotech: New Industry Voices: Place your bets--A horse race emerges in the migraine space by Randall Schatzman, CEO of Alder. Article | Follow @FierceBiotech

@JohnCFierce: Another round of biotech IPOs is drawing near. ICYMI Friday | Follow @JohnCFierce

@Ry_McBride: GSK has given itself a dose (or doses) of online collaboration for its sales organization. More from InformationWeek | Follow @Ry_McBride

@EmilyMFierce: Potential Parkinson's-fighting compounds identified. FierceBiotech Research article | Follow @EmilyMFierce

> Cellceutix ($CTIX) has acquired virtually all of the assets from bankrupt Polymedix, including a mid-stage antibiotic. The buyout gives Cellceutix 9 molecules and Polymedix's old lab equipment. Story

> BioMotiv and New York University have formed Orca Pharmaceuticals, which aims to develop an oral drug for psoriasis. Story

> Rep. Jared Huffman (D-San Rafael, CA) has gotten involved in a drama involving a compassionate use request for one of BioMarin's ($BMRN) drugs. The lawmaker says BioMarin is considering putting a patient in one of its studies for the PARP inhibitor BMN 673 after officially rejecting her compassionate-use petition. Story

Medical Device News

@FierceMedDev: From FierceDiagnostics: T2 jumps into pivotal trial for Candida assay. Article | Follow @FierceMedDev

@DamianFierce: After 22 years at the helm, AMRI's CEO is stepping down at year's end. Story from FierceCRO | Follow @DamianFierce

@MarkHFierce: J&J is sizing up buyers for its Ortho Clinical Diagnostics unit. Will it go for $5B? More | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Capsugel picks up Bend Research with dispersion delivery tech. Story from FierceDrugDelivery | Follow @MichaelGFierce

> Baxter finally closes $4B Gambro deal, eyes dialysis dominance. More

> CeQur's insulin pump draws $27M Series B. Article

> Sapheon nails down $19.8M for varicose vein treatment. Report

Pharma News

@FiercePharma: Onyx investors sue over $10.4B Amgen buyout, saying too favorable to Amgen. More from Bloomberg | Follow @FiercePharma

@EricPFierce: FDA approval of Abraxane for pancreatic cancer should extend lives for patients and sales for Celgene. ICYMI Friday | Follow @EricPFierce

@CarlyHFierce: GlaxoSmithKline selling two drinks brands to Japan's Suntory. Release | Follow @CarlyHFierce

> GlaxoSmithKline's China probe triggers U.S. bribery investigation. Article

> Boehringer targets sales reps in new round of French job cuts. Report

> Bayer's Xarelto faces stepped-up reports of side effects, deaths. Story

CRO News

> Novella shuffles execs as Quintiles deal pends. Item

> AMRI chief stepping down at year's end. News

> Patheon posts Banner quarter on 30% sales surge. Article

> Covance teams with Indiana U. for early trials. Story

> Capsugel snaps up Bend with eye on oral formulations. More

Biotech IT News

> GlaxoSmithKline picks up online collaboration tools for medical staffers. Report

> Texas biotech software outfit trumpets open source tools. Item

> Genentech backs development of video game for kids with cancer. More

> In growing diabetes market, Sanofi looks beyond iPhone for mobile glucose testing. Story

> Accelrys scoops up Bay Area software firm for $15.3M. Article

And Finally… Living Proof, the hair products company that relies on some of the science to come from the lab of MIT's prolific Robert Langer, has launched a new product. Release

Suggested Articles

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.

Fresh off Tilos Therapeutics’ $773 million sale to Merck, Barbara Fox is taking the helm of another Cambridge-based company: Rheos Medicines.

The data tee Seattle Genetics up to file for FDA approval of a TKI inhibitor it paid $614 million to acquire last year.